CVS shares fell 12.5% despite higher 2026 guidance, suggesting investors focused on the uncertainty and execution risks around the announced separation into two companies. The excerpt also flags healthcare cost trends that remain elevated, though management said they were broadly in line with expectations.
CVS Health's stock fell 7.9% following the earnings release as investors were disappointed by signs of deceleration in key segments and cautious outlook indicators, despite management’s emphasis on growth initiatives and raised full-year guidance.
CVS Health's shares rose 8.2% following a better-than-expected quarter marked by an increased full-year adjusted EPS guidance and strong operational execution across segments.
CVS Health reported strong third-quarter results with adjusted earnings per share rising to $1.60, prompting an increase in full-year guidance. The diversified business strategy shows promise, despite challenges in Health Care Delivery.